Objective: Liquid biopsy for detection of circulating tumor DNA (ctDNA) offers a promising, non-invasive strategy for real-time monitoring of cancer. We aimed to develop a universal and sensitive one-tube droplet digital PCR (ddPCR) multiplex assay able to detect ctDNA in plasma from metastatic prostate cancer (PCa) patients. Methods: Publicly available array data are applied to identify methylation signatures specific to both normal and cancerous prostate tissue. The assay is based on the highly sensitive ddPCR technology, and tissue and plasma samples are analyzed using the QX600 ddPCR multiplexing platform from BioRad. Results: We identified three novel genomic regions, ACTRT2 , EVX1, and HOXD13 , containing CpG-methylation signatures specific to normal and cancerous prostate tissue. We successfully targeted the three biomarkers in a single-tube methylation-specific multiplex ddPCR (mm-ddPCR) assay along with two previously reported PCa-specific hypermethylated CpG biomarkers, DOCK2 and HAPLN3 , and the ALB reference gene. The mm-ddPCR assay consistently detected ACTRT2 , EVX1, and HOXD13 across all samples originating from prostate-derived tissue. In contrast, the HAPLN3 and DOCK2 biomarkers were predominantly detected in PCa tissue. We also demonstrate that the five ctDNA biomarkers can be detected in plasma samples from metastatic castration-resistant PCa (mCRPC) patients with a 95% CI (85%, 100%) using the mm-ddPCR assay. Conclusion: This work demonstrates that the mm-ddPCR assay offers a simple, fast, cost-effective, sensitive, and universal tool for the detection of ctDNA biomarkers in plasma from mCRPC patients. Further studies are required to explore its potential for PCa risk stratification and treatment guidance.
Prostate cancer (PCa) exhibits marked biological heterogeneity, complicating accurate identification of aggressive disease at initial diagnosis. This study investigated whether circulating tumour DNA (ctDNA) methylation markers enhance detection and risk stratification across the PCa disease continuum. Plasma samples from the initial hospital visit were obtained from 280 participants in the PerPros prostate biobank (Vejle, Denmark), all referred with suspected PCa. Following diagnostic work-up, participants were classified across the PCa disease spectrum or as biopsy-confirmed PCa-free controls. Five methylated CpG regions (DOCK2, HAPLN3, ACTRT2, EVX1, HOXD13) were analysed using multiplex ddPCR. Performance was assessed using ROC analysis and logistic regression and compared with prostate-specific antigen (PSA). Methylation markers were detectable across the PCa disease spectrum, most frequently in metastatic castration-sensitive PCa (mCSPC) (85/97; 88%). The ctDNA methylation panel discriminated mCSPC from controls with an AUC (area under the curve) of 0.88 (95% CI: 0.83–0.93). In this cohort, combining PSA (cut-off 20 µg/L) with the ctDNA methylation panel significantly improved discrimination between patients with mCSPC and locally advanced PCa compared with PSA alone (AUC 0.88; 95% CI 0.83–0.94; p < 0.001) vs. 0.78 (95% CI 0.71–0.84). In contrast, discrimination between localised/locally advanced PCa and patients with biopsy-confirmed controls was limited (AUC 0.56; 95% CI: 0.51–0.61). The ctDNA methylation panel demonstrates robust identification of metastatic PCa and can effectively differentiate mCSPC from locally advanced PCa. However, its diagnostic abilities in localised disease appear limited.
Anal squamous cell carcinoma (ASCC) is a rare gastrointestinal cancer linked to high-risk human papillomavirus (HPV) infection in approximately 90% of cases. Current circulating tumor DNA (ctDNA) approaches in ASCC primarily rely on pathogenic HPV-based biomarkers; however, these methods do not detect all HPV strains and are not applicable to HPV-negative tumors. To address this limitation, we developed a ddPCR assay targeting hypermethylated genomic CpG biomarkers, allowing ctDNA detection independent of tumor HPV status. An anal cancer methylation-specific multiplex droplet digital PCR (AnMM-ddPCR) assay was developed to target five previously described CpG biomarkers hypermethylated in ASCC: ASCL1, LHX8, WDR17, ZIC1, and ZNF582, and the ALB reference gene. Patient samples and samples from non-cancer controls were analyzed using the BioRad QX600 ddPCR multiplexing platform. CpG-methylated biomarker levels were significantly higher in ASCC tissue compared with normal tissue and whole blood. The AnMM-ddPCR assay successfully detected all five ctDNA markers in plasma from ASCC patients, achieving an AUC of 0.72 (95% CI: 0.55-0.89; P = 0.018) in baseline plasma samples from ASCC patients with T1 or T2 tumors ≤4 cm, versus 0.90 (95% CI: 0.76-1.00; P = 0.0005) in plasma from patients with T2 tumors >4 cm or T3 tumors. At a specificity of 91.30%, sensitivity increased with stage from 52.94% (95% CI: 30.96-73.83) to 88.89% (95% CI: 56.50-99.43). The AnMM-ddPCR assay enables HPV-independent ctDNA detection in plasma samples from anal cancer patients and supports its evaluation in future liquid biopsy applications.